The treatment of patients with renal cell carcinoma (RCC) is evolving rapidly, with promising
new regimens being developed and approved for patients with advanced disease …

Abstract Treatment paradigm for metastatic clear cell renal cell carcinoma (mccRCC) has
changed dramatically over the recent decades. From cytokines, interleukin-2 and interferon …

Abstract Background Tyrosine kinase inhibitors (TKIs) such as sunitinib are multitarget
antiangiogenic agents in clear cell renal cell carcinoma (ccRCC). They are widely used in …

Abstract Background Circulating tumor cells (CTCs) correlate with adverse prognosis in
patients with breast, colorectal, lung, and prostate cancer. Little data are available for renal …

Cabozantinib is an inhibitor of multiple tyrosine kinases, including AXL, MET and VEGF
receptors. Here, we describe the rationale and design for the phase II CaboPoint trial …

Introduction Significant advances have been made in the first-line therapy of metastatic renal
cell carcinoma (mRCC) since the approval of immune-based combinations, including …

Clear cell renal cell cancer (ccRCC) is a tumor of high malignancy, which can escape
apoptosis. The tumor protein p53‐inducible nuclear protein 2 (TP53INP2), known as an …

Immune checkpoint inhibitors (ICIs) have led to a significant change in the treatment of
urological tumors where several agents are currently approved. Yet, most patients …

Simple Summary First-line treatment options for metastatic clear cell renal cell carcinoma
have significantly increased. The current recommended therapeutic strategy is based on a …

Renal cell carcinoma (RCC) and its principal subtype, clear cell RCC, are the most
diagnosed kidney cancer. Despite substantial improvement over the last decades, current …